Samsung Bioepis Obtains International Certification for Information Security Management Standards

Samsung Bioepis announced on the 7th that it has obtained the international standard certification (ISO 27001) related to the Information Security Management System (ISMS).

Lim Seonghwan, CEO of BSI Korea (left), and Ko Hanseung, President of Samsung Bioepis, are posing for a commemorative photo at the ISO 27001 certification award ceremony held on the 7th at the Samsung Bioepis headquarters in Songdo, Incheon.
[Photo by Samsung Bioepis]

ISO 27001 is a system in which an accredited certification body evaluates the conformity of a company’s processes for systematically operating and managing the handling and protection of information assets.

Samsung Bioepis explained that as part of sustainable management to enhance the company’s social value, it has continuously strived to securely manage the company’s information assets and customer data. In particular, with the acquisition of the ISO 27001 certification this time, the company’s capability to continuously improve information security processes has been recognized.

Go Han-seung, President of Samsung Bioepis, said, “With this ISO certification acquisition, we have been able to prove a global-level information asset management system. We will continue to work to enhance our business competitiveness based on an information security system that partners and customers can trust.”

Meanwhile, Samsung Bioepis has been pursuing the acquisition of various international standard certifications across different sectors in the process of promoting sustainable management centered on ESG (Environmental, Social, Governance) values. This certification marks the third achievement following last year’s certifications related to environmental management (ISO 14001) and energy management (ISO 50001). Additionally, in June, the company published its second sustainability report since its founding, disclosing business performance on key ESG management tasks suited to the characteristics of the bio and pharmaceutical industries, and continuing various sustainable management activities to enhance stakeholder value.

This content was produced with the assistance of AI translation services.